1. AXL receptor tyrosine kinase inhibition improves the anti-tumor effects of CD8 + T cells by inducing CD103 + dendritic cell-mediated T cell priming.
- Author
-
Im K, Choi YJ, Kim DH, Kim DS, Ban K, Ji W, Baek IJ, Choi CM, Lee JC, and Rho JK
- Subjects
- Mice, Animals, Axl Receptor Tyrosine Kinase, Dendritic Cells, Tumor Microenvironment, Mice, Inbred C57BL, CD8-Positive T-Lymphocytes, Neoplasms drug therapy, Neoplasms metabolism
- Abstract
AXL is a member of TAM receptor family and has been highlighted as a potential target for cancer treatment. Accumulating evidence has uncovered the critical role of the AXL signaling pathway in tumor growth, metastasis, and resistance against anti-cancer drugs, as well as its association with cancer immune escape. However, the function of AXL as a manipulator of the immune system in the tumor microenvironment (TME) remains unclear. Therefore, in this study, we investigated the impact of AXL on immune cells in the TME of a syngeneic tumor model using AXL knockout (AXL
-/- ) mice. Compared to AXL wild-type (AXL+/+ ) mice, tumor growth was significantly suppressed in AXL-/- mice, and an induced population of tumor-infiltrated CD8+ T cells and CD103+ dendritic cells (DCs) was observed. The change of CD8+ T cells and CD103+ DCs was also confirmed in tumor-draining lymph nodes (TdLN). In addition, the clonal expansion of OVA-specific CD8+ T cells was dominant in AXL-/- mice. Finally, anti-PD-1 treatment evidenced synergistic anti-cancer effects in AXL-/- mice. Overall, our data indicate that AXL signaling may inhibit the clonal expansion of tumor-specific CD8+ T cells through the regulation of the migration of CD8+ T cells and DCs in TME. Thus, AXL may be a powerful molecular target to improve anti-cancer effects through single or combined therapy with immune checkpoint inhibitors (ICI)., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2023 Elsevier Inc. All rights reserved.)- Published
- 2023
- Full Text
- View/download PDF